Loxo Links And Colorectal Cancer Data Put Array In M&A Spotlight
Executive Summary
Following Lilly's proposed acquisition of Loxo, other possible takeover targets in the precision medicine field have emerged and Array, armed with more positive data on its colorectal cancer triplet, is near the top of the list.
You may also be interested in...
Array's Three Value Drivers Align With Pfizer's Three Oncology Pillars In $11.4bn Deal
Pfizer is buying Array for a 62% premium, citing its Braftovi/Mektovi drug combo, pipeline of targeted cancer therapies and royalty revenue from partnered assets as key value drivers, aligning with the three pillars the big pharma recently outlined for its oncology strategy.
Deal Watch: Celgene Makes Alliances With Kyn, Obsidian After Bristol Buyout
Just two weeks after agreeing on a merger with Bristol, Celgene is back at its own deal-making, signing cancer-focused R&D pacts with Kyn and Obsidian. Boehringer and Bioharmony collaborate on novel therapies for hospital-acquired infections, while Sanofi teams with Biomunex on bi- and multi-specific antibodies.
Lift-Off For Lilly In Cancer Genetics With Loxo Buy
The New Year is just a week old but the biopharma merger and acquisitions merry-go-round is already spinning furiously as Lilly now steps in with a proposal to buy Loxo.